Company News
Sun Pharma Philogen Fibromun Nidlegy Clinical Updates
Sun Pharma's partner Philogen reported that Fibromun's Phase II FLASH (STS) and GLIOSTAR (glioblastoma) trials both failed to meet their primary endpoints.
Nidlegy's Phase II Duncan study showed 52.6%
